About Talecris Biotherapeutics
Talecris Biotherapeutics is a Healthcare company based in Durham (United States) founded in 2005, and was acquired by Grifols in June 2010. Plasma-derived therapies are developed for immunology, pulmonology, and related fields. Its focus areas include Diversified Pharmaceuticals.
Company details
Talecris Biotherapeutics was founded in 2005 in Durham, United States, with operations centered on plasma-derived protein therapies in sectors such as immunology, pulmonology, neurology, critical care, and hemostasis. Products developed include Gamunex for immune deficiencies and autoimmune conditions, Prolastin for alpha-1 antitrypsin deficiency, hyperimmune preparations for hepatitis and rabies, and albumin solutions like Plasbumin. The company was acquired by Grifols for 3.4 billion.
- Headquarters Durham, United States
- Stage Acquired
- SectorsHealthcare
- Website talecris.com
- Social LinkedIn
- Acquired by Grifols (Jun 2010)
Investors in Talecris Biotherapeutics
Talecris Biotherapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Grifols.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Plasma-derived therapies are developed to treat multiple diseases. | 1909 | grifols.com | Barcelona, Spain |
Investor details for Talecris Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Talecris Biotherapeutics
217 people are tracked at Talecris Biotherapeutics (87 in leadership, 16 in board & advisors, 114 in team).
| Name | Role | Group |
|---|---|---|
Gary Bouton | Regional Sales Director - Pulmonary | Leadership |
Steffen Mager | Vice President Biopharma Sales & Commercial Operations Europe | Leadership |
Víctor Grífols Deu | Co-CEO | Leadership |
Raimon Grífols Roura | Co-CEO | Leadership |
Thomas Ardiles | Global Medical Director Pulmonary And Critical Care | Leadership |
Deborah Gelinas | Medical Director | Leadership |
Bernie Bao | Director, Commercial Technical Support，g.china & APAC | Leadership |
Mary F Pascucci Do | Laboratory Director/center Medical Director - Biomat | Leadership |
Robert Morell | Center Medical Director And Laboratory Director Grifols -eglin Fort Walton Beach Biomat | Leadership |
Ryan Means | Regional Sales Director | Leadership |
Jim Martinec | Director, Head Of North America Customer Marketing | Leadership |
Jose L. Fernández Sevillano | Head Of Market Access - Iberia | Leadership |
Mary Davis | Regional Sales Director | Leadership |
Sílvia Solé Suñer | Director, Dxcts Global Response & Training | Leadership |
June Davis | Vp, Global Medical Affairs | Leadership |
Sarah Bonza M.D. | Center Medical Director | Leadership |
Janie Myers do Dfacos | Chief Medical Director | Leadership |
Jill Ward M.D. | Laboratory And Medical Director | Leadership |
Marilyn Rosa - Bray | Chief Medical Officer And Senior Vice President Of Global Plasma Quality & Regulatory Affairs | Leadership |
Brian Briggs | Vice President Of Sales And Marketing | Leadership |
197 more people are available in the full profile.
Complete people profiles for Talecris Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Talecris Biotherapeutics
3 dated milestones of Talecris Biotherapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Talecris Biotherapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Grifols.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Talecris Biotherapeutics (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Talecris Biotherapeutics
Talecris Biotherapeutics was founded in 2005.
Talecris Biotherapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Talecris Biotherapeutics was founded in 2005 in Durham, United States, with operations centered on plasma-derived protein therapies in sectors such as immunology, pulmonology, neurology, critical care, and hemostasis. Products developed include Gamunex for immune deficiencies and autoimmune conditions, Prolastin for alpha-1 antitrypsin deficiency, hyperimmune preparations for hepatitis and rabies, and albumin solutions like Plasbumin. The company was acquired by Grifols for 3.4 billion.
Talecris Biotherapeutics has 1 investor. Key investors include Grifols.
Yes. Talecris Biotherapeutics was acquired by Grifols in June 2010.